Clinical Trials Details

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Objective

Eligibility: Men and women 18+ years old, with diagnosis of triple negative breast cancer, Stage II or III at diagnosis, must have completed at least 6 cycles of preoperative chemotherapy, and surgery found no residual disease.

 

IRB Protocol Number

A012103

Clinical Trial Categories

• Breast Cancer